These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 31915169)

  • 1. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration.
    Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W
    BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders' perspectives.
    Clausen M; Mighton C; Kiflen R; Sebastian A; Dai WF; Mercer RE; Beca JM; Isaranuwatchai W; Chan KKW; Bombard Y
    CMAJ Open; 2020; 8(4):E772-E778. PubMed ID: 33234584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
    Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
    Dai WF; Arciero V; Craig E; Fraser B; Arias J; Boehm D; Bosnic N; Caetano P; Chambers C; Jones B; Lungu E; Mitera G; Potashnik T; Reiman A; Ritcher T; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group
    Curr Oncol; 2021 Oct; 28(5):4174-4183. PubMed ID: 34677272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise.
    Dai WF; Craig E; Fraser B; Chambers A; Mai H; Brown MB; Earle CC; Evans WK; Geirnaert M; Taylor M; Trudeau M; Sperber D; Beca JM; Denburg A; Mercer RE; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2021 Nov; 28(6):4645-4654. PubMed ID: 34898572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
    Parmar A; Dai WF; Dionne F; Geirnaert M; Denburg A; Ahuja T; Beca J; Bouchard S; Chambers C; Hunt MJ; Husereau D; Lungu E; McDonald V; Mercer RE; Mitera G; Muñoz C; Naipaul R; Peacock S; Potashnik T; Tadrous M; Takhar P; Taylor M; Trudeau M; Wasney D; Gavura S; Chan KKW
    Curr Oncol; 2023 Mar; 30(4):3776-3786. PubMed ID: 37185399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 8. Engaging Patients in the Canadian Real-World Evidence for Value in Cancer Drugs (CanREValue) Initiative: Processes and Lessons Learned.
    Evans WK; Takhar P; McDonald V; Elias M; Binder L; Michaud S; Tadrous M; Muñoz C; Chan KKW
    Curr Oncol; 2022 Aug; 29(8):5616-5626. PubMed ID: 36005181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.
    Takhar P; Geirnaert M; Gavura S; Beca J; Mercer RE; Denburg A; Muñoz C; Tadrous M; Parmar A; Dionne F; Boehm D; Chambers C; Craig E; Trudeau M; Cheung MC; Houlihan J; McDonald V; Pechlivanoglou P; Taylor M; Wasylenko E; Wranik WD; Chan KKW
    Curr Oncol; 2024 Apr; 31(4):1876-1898. PubMed ID: 38668044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
    Deverka PA; Douglas MP; Phillips KA
    Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs.
    Costa S; Bentley C; Regier DA; McTaggart-Cowan H; Mitton C; Burgess MM; Peacock SJ
    BMC Public Health; 2019 Jul; 19(1):977. PubMed ID: 31331312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing a Canadian Real-World Evidence Action Plan across the Drug Life Cycle.
    Tadrous M; Ahuja T; Ghosh B; Kropp R
    Healthc Policy; 2020 May; 15(4):41-47. PubMed ID: 32538348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative.
    Orsini LS; Monz B; Mullins CD; Van Brunt D; Daniel G; Eichler HG; Graff J; Guerino J; Berger M; Lederer NM; Jonsson P; Schneeweiss S; Wang SV; Crown W; Goettsch W; Willke RJ
    Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1504-1513. PubMed ID: 32924243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.